SEP 1 3 2010 W

Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 3800024.00324/1112US

Application No. 10/590,119

List of Patents and Publications for Applicant's Information Disclosure Statement

Applicant Zhi *et al*.

Filing Date
June 11, 2007

Group Art Unit 1625

(37 CFR §1.98(b))

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2010/0069379	03/18/10	Zhi et al.	514	230.5	11/13/09
	AB	7,696,246	04/13/10	Zhi et al.	514	457	06/23/05
	AC	7,727,980	06/01/10	Zhi et al.	514	215	01/31/06

	Foreigi	Patent Doc	uments or Pu	ublished Foreign	Patent A	Application	าร	
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	lation No
	!			None				

Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document			
	AD	Kapil et al., "Phase I clinical trial of LGD-4033, a novel selective androgen receptor modulator (SARM)," 14th International Congress of Endocrinology, Kyoto, Japan, March 26-30, 2010, 1 page [poster presentation].			
	AE	Vadja et al., "LGD-4033 builds muscle and bone with reduced prostate activity and may be beneficial in age-related frailty," Gerontological Society of America 62nd Annual Scientific Meeting, Atlanta, Georgia, Nov. 18-22, 2009, 1 page [poster presentation].			

Examiner Signature

Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.